Histone acetyl transferases as emerging drug targets

Drug Discovery Today

Volumn 14, Issue 19-20, 2009, Pages 942-948

  Dekker, Frank J ^a   Haisma, Hidde J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLOROISOTHIAZOLONE; ALPHA METHYLENE BUTYROLACTONE DERIVATIVE; ANACARDIC ACID; CURCUMIN; GARCINOL; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE CBP; HISTONE ACETYLTRANSFERASE GCN5; HISTONE ACETYLTRANSFERASE INHIBITOR; HISTONE ACETYLTRANSFERASE P300; HISTONE ACETYLTRANSFERASE PCAF; ISOGARCINOL; ISOTHIAZOLONE; ISOTHIAZOLONE DERIVATIVE; LTK 14; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ACETYLATION; ANTIBACTERIAL ACTIVITY; ASTHMA; CHEMICAL GENETICS; CHEMICAL MODIFICATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG DESIGN; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; EPIGENETICS; HEART FAILURE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; LEARNING DISORDER; MEMORY DISORDER; MOLECULAR INTERACTION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION REGULATION; VIRUS INFECTION;

ACETYLATION; ANIMALS; CREB-BINDING PROTEIN; DRUG DESIGN; ENZYME INHIBITORS; EPIGENESIS, GENETIC; HISTONE ACETYLTRANSFERASES; HISTONES; HUMANS; LYSINE; MOLECULAR STRUCTURE; P300-CBP TRANSCRIPTION FACTORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70349311616     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.06.008     Document Type: Review

References (65)

1. Beckett D. Regulated assembly of transcription factors and control of transcription initiation. J. Mol. Biol. 314 (2001) 335-352
2. Kouzarides T. Chromatin modifications and their function. Cell 128 (2007) 693-705
3. Strahl B.D., and Allis C.D. The language of covalent histone modifications. Nature 403 (2000) 41-45
4. Bird A. Perceptions of epigenetics. Nature 447 (2007) 396-398
5. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 8 (2007) 286-298
6. Nagy Z., and Tora L. Distinct GCN5/PCAF-containing complexes function as co-activators and are involved in transcription factor and global acetylation. Oncogene 26 (2007) 5341-5357
7. Vogelauer M., et al. Global histone acetylation and deacetylation in yeast. Nature 408 (2000) 495-498
8. Seligson D.B., et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435 (2005) 1262-1266
9. Suganuma T., and Workman J.L. Crosstalk among histone modifications. Cell 135 (2008) 604-607
10. Cheung P., et al. Synergistic coupling of histone H3 phosphorylation and acetylation in response to epidermal growth factor stimulation. Mol. Cell 5 (2000) 905-915
11. Walter W., et al. 14-3-3 interaction with histone H3 involves a dual modification pattern of phosphoacetylation. Mol. Cell. Biol. 28 (2008) 2840-2849
12. Li S., and Shogren-Knaak M.A. The Gcn5 bromodomain of the SAGA complex facilitates cooperative and cross-tail acetylation of nucleosomes. J. Biol. Chem. 284 (2009) 9411-9417
13. Cameron E.E., et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21 (1999) 103-107
14. Hodawadekar S.C., and Marmorstein R. Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design. Oncogene 26 (2007) 5528-5540
15. Marmorstein R., and Trievel R.C. Histone modifying enzymes: structures, mechanisms, and specificities. Biochim. Biophys. Acta 1789 (2009) 58-68
16. Schiltz R.L., et al. Overlapping but distinct patterns of histone acetylation by the human coactivators p300 and PCAF within nucleosomal substrates. J. Biol. Chem. 274 (1999) 1189-1192
17. Avvakumov N., and Cote J. The MYST family of histone acetyltransferases and their intimate links to cancer. Oncogene 26 (2007) 5395-5407
18. Vetting M.W., et al. Structure and functions of the GNAT superfamily of acetyltransferases. Arch. Biochem. Biophys. 433 (2005) 212-226
19. Gayther S.A., et al. Mutations truncating the EP300 acetylase in human cancers. Nat. Genet. 24 (2000) 300-303
20. Bandyopadhyay D., et al. Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes. Cancer Res. 62 (2002) 6231-6239
21. Ait-Si-Ali S., et al. CBP/p300 histone acetyl-transferase activity is important for the G1/S transition. Oncogene 19 (2000) 2430-2437
22. Iyer N.G., et al. p300 is required for orderly G1/S transition in human cancer cells. Oncogene 26 (2007) 21-29
23. Kitabayashi I., et al. Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a t(8;22)(p11;q13) chromosome translocation. Leukemia 15 (2001) 89-94
24. Katsumoto T., et al. Roles of the histone acetyltransferase monocytic leukemia zinc finger protein in normal and malignant hematopoiesis. Cancer Sci. 99 (2008) 1523-1527
25. Howe L., et al. Histone H3 specific acetyltransferases are essential for cell cycle progression. Genes Dev. 15 (2001) 3144-3154
26. Adcock I.M., et al. Epigenetic regulation of airway inflammation. Curr. Opin. Immunol. 19 (2007) 694-700
27. Barnes P.J., et al. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur. Respir. J. 25 (2005) 552-563
28. Ito K., et al. Expression and activity of histone deacetylases in human asthmatic airways. Am. J. Respir. Crit. Care Med. 166 (2002) 392-396
29. Cosío B.G., et al. Histone acetylase and deacetylase activity in alveolar macrophages and blood monocytes in asthma. Am. J. Respir. Crit. Care Med. 170 (2004) 141-147
30. Clarke D.L., et al. PKCbetaII augments NF-kappaB-dependent transcription at the CCL11 promoter via p300/CBP-associated factor recruitment and histone H4 acetylation. J. Immunol. 181 (2008) 3503-3514
31. Barrett R.M., and Wood M.A. Beyond transcription factors: the role of chromatin modifying enzymes in regulating transcription required for memory. Learn. Mem. 15 (2008) 460-467
32. Maurice T., et al. Altered memory capacities and response to stress in p300/CBP-associated factor (PCAF) histone acetylase knockout mice. Neurophychopharmacology 33 (2008) 1584-1602
33. Cereseto A., et al. Acetylation of HIV-1 integrase by p300 regulates viral integration. EMBO J. 24 (2005) 3070-3081
34. Stevens M., et al. The regulation of HIV-1 transcription: molecular targets for chemotherapeutic intervention. Med. Res. Rev. 26 (2006) 595-625
35. Mantelingu K., et al. Specific inhibition of p300-HAT alters global gene expression and represses HIV replication. Chem. Biol. 14 (2007) 645-657
36. Lau O.D., et al. HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol. Cell 5 (2000) 589-595
37. Sagar V., et al. Bisubstrate analogue structure-activity relationships for p300 histone acetyltransferase inhibitors. Bioorg. Med. Chem. 12 (2004) 3383-3390
38. Zheng Y., et al. Synthesis and evaluation of a potent and selective cell-permeable p300 histone acetyltransferase inhibitor. J. Am. Chem. Soc. 127 (2005) 17182-17183
39. Poux A.N., et al. Structure of the GCN5 histone acetyltransferase bound to a bisubstrate inhibitor. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 14065-14070
40. Balasubramanyam K., et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J. Biol. Chem. 279 (2004) 51163-51171
41. Costi R., et al. Cinnamoyl compounds as simple molecules that inhibit p300 histone acetyltransferase. J. Med. Chem. 50 (2007) 1973-1977
42. Morimoto T., et al. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J. Clin. Invest. 118 (2008) 868-878
43. Balasubramanyam K., et al. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J. Biol. Chem. 279 (2004) 33716-33726
44. Arif M., et al. Mechanism of p300 specific histone acetyltransferase inhibition by small molecules. J. Med. Chem. 52 (2009) 267-277
45. Balasubramanyam K., et al. Small molecule modulators of histone acetyltransferase p300. J. Biol. Chem. 278 (2003) 19134-19140
46. Souto J.A., et al. Synthesis of benzamides related to anacardic acid and their histone acetyltransferase HAT inhibitory activities. ChemMedChem 3 (2008) 1435-1442
47. Sbardella G., et al. Identification of long alkylidenemalonates as novel small molecule modulators of histone acetyltransferases. Bioorg. Med. Chem. Lett. 18 (2008) 2788-2792
48. Sung B., et al. Anacardic acid (6-nonadecyl salicylic acid), an inhibitor of histone acetyltransferase, suppresses expression of nuclear factor-kappaB-regulated gene products involved in cell survival, proliferation, invasion, and inflammation through inhibition of the inhibitory subunit of nuclear factor-kappaBalpha kinase, leading to potentiation of apoptosis. Blood 111 (2008) 4880-4891
49. Biel M., et al. Design, synthesis and biological evaluation of a small-molecule inhibitor of the histone acetyltransferase Gcn5. Angew. Chem. Int. Ed. 43 (2004) 3974-3976
50. Stimson L., et al. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Mol. Cancer Ther. 4 (2005) 1521-1532
51. Clerici F., et al. Isothiazoles. Part 14: new 3-aminosubstituted isothiazole dioxides and their mono- and dihalogeno derivatives. Tetrahedron 59 (2003) 9399-9408
52. Dekker F.J., et al. Inhibition of the PCAF histone acetyl transferase and cell proliferation by isothiazolones. Bioorg. Med. Chem. 17 (2009) 460-466
53. Gorsuch S., et al. Synthesis of isothiazol-3-one derivatives as inhibitors of histone acetyltransferases (HATs). Bioorg. Med. Chem. 17 (2009) 467-474
54. Khalaj A., et al. Synthesis and antibacterial activity of 2-(4-substituted phenyl)-3(2H)-isothiazolones. Eur. J. Med. Chem. 39 (2004) 699-705
55. Morley J.O., et al. Structure-activity relationships in 3-isothiazolones. Org. Biomol. Chem. 3 (2005) 3713-3719
56. Basketter D., et al. Skin sensitization risk assessment: a comparative evaluation of 3 isothiazolinone biocides. Contact Dermatitis 40 (1999) 150-154
57. Alvarez-Sánchez R., et al. Studies of chemical selectivity of haptens, reactivity, and skin sensitization potency. 3. Synthesis and studies on the reactivity towards model nucleophiles of the 13C labeled skin sensitizers, 5-chloro-2-methylisothiazol-3-one (MCI) and 2-methylisothiazol-3-one (MI). Chem. Res. Toxicol. 16 (2003) 627-638
58. Morley J.O., et al. Kinetic studies on the reactions of 3-isothiazolones with 2-methyl-2-propanethiol. Int. J. Chem. Kinet. 39 (2006) 254-260
59. Dekker F.J., et al. Protein structure similarity clustering (PSSC) and natural product structure as inspiration sources for drug development and chemical genomics. Curr. Opin. Chem. Biol. 9 (2005) 232-239
60. Balamurugan R., et al. Design of compound libraries based on natural product scaffolds and protein structure similarity clustering (PSSC). Mol. Biosyst. 1 (2005) 36-45
61. Dekker F.J., et al. Amino propynyl benzoic acid building block in rigid spacers of divalent ligands binding to the Syk SH2 domains with equally high affinity as the natural ligand. Bioorg. Med. Chem. Lett. 13 (2003) 1241-1244
62. Dekker F.J., et al. Role of solution conformation and flexibility of short peptide ligands that bind to the p56(lck) SH2 domain. Bioorg. Med. Chem. 11 (2003) 941-949
63. Dekker F.J., et al. Replacement of the intervening amino acid sequence of a Syk-binding diphosphopeptide by a nonpeptide spacer with preservation of high affinity. Chembiochem 3 (2002) 238-242
64. Lau O.D., et al. p300/CBP-associated factor histone acetyltransferase processing of a peptide substrate. Kinetic analysis of the catalytic mechanism. J. Biol. Chem. 275 (2000) 21953-22159
65. Cebrat M., et al. Synthesis and analysis of potential prodrugs of coenzyme A analogues for the inhibition of the histone acetyltransferase p300. Bioorg. Med. Chem. 11 (2003) 3307-3313